However, clinical trials in Rett patients treated with saritozan, a 5HT1aR- and D2R-agonist, were unsuccessful (Evaluation of the Efficacy, Safety, and Tolerability of Sarizotan in Rett Syndrome with Respiratory Symptoms (STARS), 2021). Here, DRD2 is linked to atypical Rett syndrome.